← Leaderboards
Gunda I. Georg
University Of Kansas Lawrence
$26,008,014
Attributed
$30,034,098
Total exposure
27
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$50,541,051 · 30
By mechanism
P20$14,623,253 · 8
U54$10,642,712 · 5
R01$7,595,323 · 7
P50$5,955,872 · 3
U01$5,455,024 · 2
R42$2,907,583 · 1
Top collaborators
- V Gustavo Blanco5 shared
- Vargheese Mani Chennathukuzhi4 shared
- Walter C Low3 shared
- Michael J Smanski3 shared
- Aleksandar Rajkovic2 shared
Others in their field
Top investigators on “Male Contraceptive Agents”
- Clint Dart · Health Decisions, Inc.$24,473,652
- Christina Wang · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center$19,987,877
- William Bremner · University Of Washington$12,853,368
- Martin M Matzuk · University Of Missouri-Columbia$9,949,963
- Ronald H Gray · Johns Hopkins University$9,322,695
- Bashir Kaskar · Ash Stevens, Inc.$8,559,393
Research focus
Male Contraceptive AgentsPropertyIn VivoContraceptive AgentsLeadContraceptive MethodsProteinsBasePharmaceutical PreparationsDrug Design /Synthesis /ProductionUniversitiesDrug KineticsIn VitroResearch PersonnelAnimalsInhibitor/AntagonistSmall MoleculeGrantDrug DiscoverySperm CellPharmaceutical ChemistryClinical TrialsMaleDrug Development
Grant awards (86)
Catsper Inhibitors for Male Contraception$375,000
R61 · FY2025 · HD · contact PI
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease$283,246
R42 · FY2025 · AG
DEL Screening Campaign for Contraceptive and Cancer Targets$193,750
R21 · FY2025 · HD · contact PI
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease$1,280,101
R42 · FY2024 · AG
Targeting Na,K-ATPase alpha4 for male contraception$504,380
R01 · FY2024 · HD
Catsper Inhibitors for Male Contraception$401,250
R61 · FY2024 · HD · contact PI
DEL Screening Campaign for Contraceptive and Cancer Targets$232,500
R21 · FY2024 · HD · contact PI
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease$1,344,236
R42 · FY2023 · AG
Targeting Na,K-ATPase alpha4 for male contraception$530,419
R01 · FY2023 · HD
Targeting Na,K-ATPase alpha4 for male contraception$512,936
R01 · FY2022 · HD
Targeting Na,K-ATPase alpha4 for male contraception$497,605
R01 · FY2021 · HD
Contraceptive Discovery, Development and Behavioral Research Center$1,928,523
P50 · FY2020 · HD · contact PI
Drug Discovery and Development Core$765,837
P50 · FY2020 · HD · contact PI
Targeting Na,K-ATPase alpha4 for male contraception$544,926
R01 · FY2020 · HD
Allosteric CDK2 inhibitor Discovery and Development for Male Contraception$376,172
R61 · FY2020 · HD · contact PI
Administrative Core$337,192
P50 · FY2020 · HD · contact PI
Contraceptive Discovery, Development and Behavioral Research Center$1,928,523
P50 · FY2019 · HD · contact PI
Drug Discovery and Development Core$662,459
P50 · FY2019 · HD · contact PI
Allosteric CDK2 inhibitor Discovery and Development for Male Contraception$403,582
R61 · FY2019 · HD · contact PI
Administrative Core$333,338
P50 · FY2019 · HD · contact PI
Small molecule GPR10 antagonists for the treatment of uterine fibroids$302,002
R01 · FY2019 · HD
Contraceptive Discovery, Development and Behavioral Research Center$1,928,523
U54 · FY2018 · HD · contact PI
Drug Discovery and Development Core$757,838
U54 · FY2018 · HD · contact PI
Administrative Core$320,732
U54 · FY2018 · HD · contact PI
Small molecule GPR10 antagonists for the treatment of uterine fibroids$302,026
R01 · FY2018 · HD
Contraceptive Discovery, Development and Behavioral Research Center$2,473,290
U54 · FY2017 · HD · contact PI
Drug Discovery and Development Core$1,137,714
U54 · FY2017 · HD · contact PI
Administrative Core$403,173
U54 · FY2017 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$846,387
U01 · FY2016 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$844,069
U01 · FY2015 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$851,746
U01 · FY2014 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$841,422
U01 · FY2013 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$888,430
U01 · FY2012 · HD · contact PI
Drug Discovery & Synthesis of Contraceptive Agents$714,506
U01 · FY2012 · HD · contact PI
CORE--Drug, Discovery, Design and Synthesis$1,020,466
U54 · FY2011 · HD · contact PI
Core - Drug, Discovery, Design and Synthesis$1,124,456
U54 · FY2010 · HD · contact PI
CORE--Drug, Discovery, Design and Synthesis$442,757
U54 · FY2010 · HD · contact PI
CORE--Drug, Discovery, Design and Synthesis$580,429
U54 · FY2009 · HD · contact PI
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space$469,644
P41 · FY2009 · GM · contact PI
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space$457,024
P41 · FY2008 · GM · contact PI
CORE--Drug, Discovery, Design and Synthesis$453,334
U54 · FY2008 · HD · contact PI
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space$452,362
P41 · FY2007 · GM · contact PI
COBRE: UKS: CORE A: ADMINISTRATIVE CORE$429,247
P20 · FY2006 · RR · contact PI
COBRE: UKS: CORE C: MEDICINAL CHEMISTRY$344,809
P20 · FY2006 · RR · contact PI
Tyloindicines: Chemistry and Biology$316,129
R01 · FY2006 · CA · contact PI
Center for Cancer Experimental Therapeutics$1,786,254
P20 · FY2005 · RR
Tyloindicines: Chemistry and Biology$323,738
R01 · FY2005 · CA
CORE--MEDICINAL CHEMISTRY$299,555
P20 · FY2005 · RR
CORE--FIRST AWARD &EQUIPMENT &FACILITY SUPPORT$277,227
P20 · FY2005 · RR
COBRE: UKS: CORE A: ADMINISTRATIVE CORE$237,750
P20 · FY2005 · RR
CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS$1,976,012
P20 · FY2004 · RR
Tyloindicines: Chemistry and Biology$323,738
R01 · FY2004 · CA
CORE--FIRST AWARD &EQUIPMENT &FACILITY SUPPORT$311,814
P20 · FY2004 · RR
COBRE: UKS: CORE A: ADMINISTRATIVE CORE$249,175
P20 · FY2004 · RR
COBRE: UKS: CORE D: MEDICINAL CHEMISTRY$225,582
P20 · FY2004 · RR
CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS$1,978,280
P20 · FY2003 · RR
Updating Laboratory Facilities Under P20 RR 15563$498,847
P20 · FY2003 · RR
Tyloindicines: Chemistry and Biology$323,738
R01 · FY2003 · CA
EPOTHILONE AFFINITY LABELS$271,579
R01 · FY2003 · CA
TAXOL BRAIN DELIVERY$258,770
R01 · FY2003 · CA
EPOTHILONE AFFINITY LABELS$36,434
R01 · FY2003 · CA
CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS$1,980,477
P20 · FY2002 · RR
Tyloindicines: Chemistry and Biology$291,364
R01 · FY2002 · CA
EPOTHILONE AFFINITY LABELS$263,667
R01 · FY2002 · CA
TAXOL BRAIN DELIVERY$251,234
R01 · FY2002 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$201,659
U01 · FY2002 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$35,971
U01 · FY2002 · CA
EPOTHILONE AFFINITY LABELS$35,501
R01 · FY2002 · CA
Medicinal Chemistry$0
P20 · FY2002 · RR
CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS$1,994,714
P20 · FY2001 · RR
EPOTHILONE AFFINITY LABELS$255,988
R01 · FY2001 · CA
TAXOL BRAIN DELIVERY$243,915
R01 · FY2001 · CA
PHARMACOPHORE INTERACTIONS WITH TUBULIN OF CRYPTOPHYCINS$225,608
R01 · FY2001 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$195,784
U01 · FY2001 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$35,050
U01 · FY2001 · CA
EPOTHILONE AFFINITY LABELS$34,593
R01 · FY2001 · CA
TAXOL BRAIN DELIVERY$27,207
R01 · FY2001 · CA
Medicinal Chemistry$0
P20 · FY2001 · RR
CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS$2,033,510
P20 · FY2000 · RR
TAXOL BRAIN DELIVERY$236,811
R01 · FY2000 · CA
PHARMACOPHORE INTERACTIONS WITH TUBULIN OF CRYPTOPHYCINS$219,167
R01 · FY2000 · CA
EPOTHILONE AFFINITY LABELS$205,221
R01 · FY2000 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$196,176
R01 · FY2000 · CA
EPOTHILONE AFFINITY LABELS$33,714
R01 · FY2000 · CA
SALICYLIHALAMIDES--CHEMISTRY AND BIOLOGY$26,737
R01 · FY2000 · CA
Medicinal Chemistry$0
P20 · FY2000 · RR